Orlovskiy S, Gupta P, Roman J, Arias-Mendoza F, Nelson D, Koch C
Cancers (Basel). 2024; 16(7).
PMID: 38611062
PMC: 11010960.
DOI: 10.3390/cancers16071384.
Huang Y, Sun G, Sun X, Li F, Zhao L, Zhong R
Cancers (Basel). 2020; 12(11).
PMID: 33187214
PMC: 7696079.
DOI: 10.3390/cancers12113332.
Cruz-Gregorio A, Martinez-Ramirez I, Pedraza-Chaverri J, Lizano M
Cancers (Basel). 2019; 11(2).
PMID: 30764513
PMC: 6406552.
DOI: 10.3390/cancers11020182.
Lyons J, Song C, Ross B
J Neurooncol. 1998; 36(2):149-57.
PMID: 9525814
DOI: 10.1023/a:1005819604858.
De Cesare M, Pratesi G, Giusti A, Polizzi D, Zunino F
Br J Cancer. 1998; 77(3):434-9.
PMID: 9472640
PMC: 2151278.
DOI: 10.1038/bjc.1998.69.
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz G, Teicher B, Eder Jr J, Korbut T, Holden S, Ara G
Cancer Chemother Pharmacol. 1993; 32(6):455-62.
PMID: 8258194
DOI: 10.1007/BF00685890.
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Popert R, Masters J, Coptcoat M, Zupi G
Urol Res. 1995; 22(6):367-72.
PMID: 7740656
DOI: 10.1007/BF00296877.
Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.
Starace G, Badaracco G, Bertuzzi A, Gandolfi A, Greco C, Totaro M
J Cancer Res Clin Oncol. 1987; 113(5):451-8.
PMID: 3624301
DOI: 10.1007/BF00390039.
Phase II study of lonidamine in metastatic breast cancer.
Pronzato P, Amoroso D, Bertelli G, Conte P, Cusimano M, Ciottoli G
Br J Cancer. 1989; 59(2):251-3.
PMID: 2930690
PMC: 2247009.
DOI: 10.1038/bjc.1989.51.
The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
DeAngelis L, Currie V, Kim J, Krol G, OHehir M, Farag F
J Neurooncol. 1989; 7(3):241-7.
PMID: 2677257
DOI: 10.1007/BF00172917.
The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.
Carapella C, Paggi M, Cattani F, Ciottoli G, Floridi A, Iandolo B
J Neurooncol. 1989; 7(1):103-8.
PMID: 2666593
DOI: 10.1007/BF00149384.
Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe K, Brann T, Holden S, Teicher B, Frei 3rd E
Cancer Chemother Pharmacol. 1989; 25(1):32-6.
PMID: 2590999
DOI: 10.1007/BF00694335.
Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation.
Hong S, Alfieri A, Kim S, Kim J
Jpn J Cancer Res. 1989; 80(6):592-6.
PMID: 2503478
PMC: 5917789.
DOI: 10.1111/j.1349-7006.1989.tb01680.x.
Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher B, Herman T, Tanaka J, Dezube B, Pardee A, Frei 3rd E
Cancer Chemother Pharmacol. 1991; 28(1):45-50.
PMID: 1904012
DOI: 10.1007/BF00684955.
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
Savini S, Zoli W, Nanni O, Volpi A, Frassineti G, Magni E
Breast Cancer Res Treat. 1992; 24(1):27-34.
PMID: 1463869
DOI: 10.1007/BF01832355.